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Abstract
In an increasing proportion of cases, hepatocellular carcinoma (HCC) develops 
in patients with nonalcoholic fatty liver disease (NAFLD). Mutations in telom-
erase reverse transcriptase (hTERT) are associated with familial liver diseases. 
The aim of this study was to examine telomere length and germline hTERT 
mutations as associated with NAFLD- HCC. In 40 patients with NAFLD- HCC, 
45 with NAFLD- cirrhosis and 64 healthy controls, peripheral blood telomere 
length was evaluated by qRT- PCR and hTERT coding regions and intron–exon 
boundaries sequenced. We further analyzed 78 patients affected by primary liver 
cancer (NAFLD- PLC, 76 with HCC). Enrichment of rare coding mutations 
(allelic frequency <0.001) was evaluated by Burden test. Functional consequences 
were estimated in silico and by over- expressing protein variants in HEK- 293 
cells. We found that telomere length was reduced in individuals with NAFLD- 
HCC versus those with cirrhosis (P = 0.048) and healthy controls (P = 0.0006), 
independently of age and sex. We detected an enrichment of hTERT mutations 
in NAFLD- HCC, that was confirmed when we further considered a larger cohort 
of NAFLD- PLC, and was more marked in female patients (P = 0.03). No muta-
tions were found in cirrhosis and local controls, and only one in 503 healthy 
Europeans from the 1000 Genomes Project (allelic frequency = 0.025 vs. <0.001; 
P = 0.0005). Mutations with predicted functional impact, including the frameshift 
Glu113Argfs*79 and missense Glu668Asp, cosegregated with liver disease in two 
families. Three patients carried missense mutations (Ala67Val in homozygosity, 
Pro193Leu and His296Pro in heterozygosity) in the N- terminal template- binding 
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Introduction
Following the epidemics of obesity and insulin resistance, 
nonalcoholic fatty liver disease (NAFLD) is becoming a major 
cause of hepatocellular carcinoma (HCC) in Western coun-
tries [1]. NAFLD- HCC patients are most commonly older 
males with type 2 diabetes and meeting criteria for at least 
one feature of the metabolic syndrome, mostly unaware of 
being affected by a progressive form of liver disease [2–5]. 
Although the growing rates of HCC may be due to the 
increased number of individuals with advanced fibrosis, 
NAFLD- HCC develops in patients without cirrhosis more 
frequently than in liver disease caused by other factors, sug-
gesting steatosis directly promotes hepatic carcinogenesis 
[5–7]. This complex clinical presentation renders classic 
screening strategies for early detection of HCC ineffective.
Family history and genetic factors play important roles 
in the pathogenesis of progressive NAFLD and of HCC 
[8, 9]. In particular, the common PNPLA3 I148M muta-
tion increases the risk of NAFLD and favors hepatic car-
cinogenesis [1, 10, 11]. However, although the presence 
of the 148M mutation has a relatively high specificity, it 
lacks sensitivity to be used as single marker for NAFLD- 
HCC risk stratification [12]. Therefore, there is still an 
urgent need of prognostic biomarkers able to identify 
NAFLD patients at risk of HCC.
Rare mutations inducing Mendelian diseases due to 
severe derangements in the function of encoded proteins 
may also be involved in predisposition to NAFLD- HCC. 
Indeed, mutations in APOB have been linked to familial 
cases through predisposition toward development of severe 
steatosis [13]. While acquired activating mutations in the 
telomerase reverse transcriptase (hTERT) promoter are 
commonly observed during hepatic carcinogenesis [14], 
loss- of- function germline mutations in hTERT can pre-
dispose to a spectrum of familial liver diseases character-
ized by steatosis [15] and possible evolution to cirrhosis 
and HCC [16, 17]. We previously reported the occurrence 
of NAFLD- HCC in a patient with an hTERT loss- of- 
function mutation [18]. TERT encodes the catalytic reverse 
transcriptase subunit of the enzymatic complex responsible 
for maintaining telomere length. Telomeres are repetitive 
DNA sequences at the end of the genes responsible for 
protecting chromosomes tips, which shorten during each 
round of cell division [19]. Therefore, telomere attrition 
is exacerbated in degenerative conditions characterized by 
chronic injury and regeneration with accelerated cell turno-
ver [20]. Shortened telomeres play a causal role in the 
pathogenesis of liver fibrosis by inducing senescence 
[21–24], and eventually predispose to HCC because short 
telomeres do not effectively protect from chromosomal 
rearrangements during cell replication [25].
The aim of this study was to examine whether periph-
eral blood telomere length and in particular rare germline 
hTERT mutations (main outcome) are associated with 
NAFLD- HCC development. Furthermore, we characterized 
the functional impact of the identified hTERT mutations 
by using both in silico and in vitro approaches.
Materials and Methods
Study design
The study design is shown in Figure S1. During phase 1 
we investigated the presence of rare germline hTERT cod-
ing mutations. We defined rare coding mutations as vari-
ations with allelic frequency <0.001, according to two of 
largest frequency database available namely ExAC (Exome 
Aggregation Consortium) in the Non- Finnish European 
(NFE) population and ESP (Exome Sequencing Project) 
European- American (EA) population. The mutation fre-
quency was compared to that of local controls and European 
individuals included in the 1000G (n = 503). Furthermore, 
we evaluated telomere length on a discovery cohort of 
Italian NAFLD- HCC (n = 40), NAFLD- cirrhosis (n = 45), 
and healthy individuals (n = 64) of comparable age and 
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domain (P = 0.037 for specific enrichment). Besides Glu668Asp, the Ala67Val 
variant resulted in reduced intracellular protein levels. In conclusion, we detected 
an association between shorter telomeres in peripheral blood and rare germline 
hTERT mutations and NAFLD- HCC.
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sex distribution. In phase 2, we attempted replication in 
a validation cohort including both Italian and Northern 
European subjects with NAFLD, who developed primary 
liver cancer (PLC, 97% with HCC). We subsequently con-
ducted family studies to test for segregation of the hTERT 
mutations with liver disease. Finally, we examined the 
functional effects of the coding mutations identified by 
bioinformatics using a combination of in silico prediction 
tools and in vitro by cell studies with overexpression of 
recombinant wild- type and mutated proteins.
Patients
In phase 1, we enrolled 40 patients with NAFLD- HCC: 
20 from Policlinico Hospital of Milan, 4 from S. Giovanni 
Battista Hospital of Turin, 1 from the Gastroenterology 
Unit of Palermo, and the remaining 15 from the Hospital 
of Udine. The diagnosis of HCC was based on the EASL- 
EORTC Clinical Practice Guidelines for management of 
hepatocellular carcinoma [26]. Additionally, 45 patients 
affected by NAFLD cirrhosis were enrolled in order to 
confirm the association of the mutations eventually found 
with the carcinogenic phenotype (20 from Palermo and 
25 from Milan). Secondary causes of steatosis were excluded 
on history, including alcohol abuse (≥ 30 g/day in M/F) 
and the use of drugs known to precipitate steatosis. Viral 
and autoimmune hepatitis, hereditary hemochromatosis, 
Wilson’s disease, alpha- 1- antitrypsin deficiency, and present 
or previous infection with HBV (HBsAg and HBsAb) and 
HCV were ruled out using standard clinical and labora-
tory evaluation as well as liver biopsy features. For all 
patients, complete clinical data and follow- up are available 
in Table 1. Missing data (representing less than 5% for 
each category) have been replaced by the median for each 
category. Samples were collected from January 2012 until 
December 2013.
We also analyzed a local ethnically matched control 
group of comparable sex distribution including 64 healthy 
blood donors without clinical and biochemical evidence 
of liver disease and no alcohol abuse [27]. Presence of 
rare germline hTERT mutations was also searched for in 
503 European individuals included in the 1000 Genomes 
database (http://www.internationalgenome.org).
In the second phase of the study, we examined a valida-
tion cohort collected after January 2014, including 78 patients 
affected by NAFLD- PLC, 2 of whom had intrahepatic 
cholangiocarcinoma (28 from the Freeman Hospital of 
Newcastle upon Tyne, 24 from Turin, 25 from the Policlinico 
Gemelli of Rome and 1 from Milan). We did not exclude 
NAFLD- associated intrahepatic cholangiocarcinoma in the 
validation cohort, since we could not rule out that germline 
mutations in hepatic stem cells might give rise to cancers 
with different phenotypes. All were of Caucasian ancestry. 
Clinical features are shown in Table 1.
Finally, in the family study we considered the relatives 
of two HCC patients belonging to the discovery cohort 
who carried hTERT mutations. In order to evaluate a 
genotype–phenotype correlation, liver enzymes were meas-
ured and abdominal ultrasonography and liver stiffness 
measurement were performed in family members of the 
probands.
The study protocol conformed to the ethical guidelines 
of the 1975 Declaration of Helsinki was approved by the 
ethical committee of the Fondazione IRCCS of Milan and 
was performed according to the recommendations of the 
hospitals involved. Informed consent was obtained from 
each patient or responsible guardian.
Telomere length measurement
DNA was obtained from peripheral blood leukocytes or 
liver biopsies by phenol–chloroform extraction. Quality 
Table 1. Clinical features of subjects included in the study.
Discovery cohort Validation cohort
Healthy (n = 64) Cirrhosis (n = 45) HCC (n = 40) P PLC (n = 78) P
Age, years 59.1 ± 6.6 58.8 ± 8.7 66.3 ± 9.5 <0.0001 67.5 ± 8.4 <0.0001
Sex, F 19 (30) 15 (33) 13 (33) 0.606 11 (14) 0.0239
BMI 25.5 ± 2.6 30.5 ± 4.3 28.6 ± 4.0 0.0011 30.3 ± 5.4 <0.0001
T2DM, y 0 29 (64) 24 (60) <0.0001 45 (58) <0.0001
Fibrosis, F3- 4 0 45 (100) 32 (80) <0.0001 61 (78) <0.0001
Italian origin, y 64 (100) 45 (100) 40 (100) 50 (64)
HCC, y 0 0 40 (100) 76 (97)
PNPLA3, I148M 0.0086 <0.0001
I/I 36 (56) 9 (20) 15 (37) 16 (21)
I/M 24 (38) 23 (51) 14 (35) 36 (46)
M/M 4 (6) 13 (29) 11 (28) 26 (33)
PLC, primary liver cancer; (), % values; y, yes; T2DM, type 2 diabetes mellitus; HCC, hepatocellular carcinoma; P, P value calculated as HCC versus 
healthy subjects.
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control was performed by evaluating 260/280 nmol/L 
absorbance ratio and by 1% agarose gel electrophoresis. 
Mean telomere length was measured by quantitative real- 
time polymerase chain reaction (qPCR), as previously 
described [28–31]. Briefly, PCR was conducted in triplicate 
in a 7500 Fast Real Time PCR System (Life Technologies, 
Foster City, CA) and results are presented as ratio of 
telomere repeat copy number to 36B4 single gene copy 
number, calculated considering the relative quantity of 
the two distinct PCR products.
hTERT sequencing
The prevalence of coding mutations in hTERT sequence 
was evaluated by Sanger sequencing on DNA previously 
extracted from peripheral blood leukocytes. The primers 
used for amplification and sequencing of the whole hTERT 
sequence, including the 16 exons and intron–exon bounda-
ries, are listed in Table S1.
Mutagenesis, cloning, and overexpression of 
hTERT variants
Wild- type hTERT cDNA was synthesized and cloned 
in the pcDNA 3.1 vector with a V5 epitope tag at the 
C- terminus by GeneArt Gene Synthesis (Thermo Fisher 
Scientific, Rockford, IL, USA). Single base- pair changes 
resulting in the Ala67Val or Glu668Asp substitutions 
were introduced by overlap extension PCR cloning. 
Single base- pair changes resulting into a proline to 
leucine (Pro193Leu or His296Pro) substitutions were 
introduced by site- directed mutagenesis. A detailed 
protocol for mutagenesis is available upon request. The 
PCR products were cloned in pcDNA 3.1 vector (pcDNA 
3.1 Directional TOPO expression kit; Invitrogen, 
Carlsbad, CA). The presence of the hTERT mutations 
and fidelity of each construct were confirmed by DNA 
sequencing. Human embryonic kidney cells (HEK- 293) 
were cultured in DMEM (Dulbecco’s modified Eagle’s 
medium) containing 10% FBS (fetal bovine serum). 
Expression plasmids (30 μg/T- 75 flask) containing the 
human wild- type hTERT or mutants were used to 
transfect HEK- 293 cells using Lipofectamine 3000 
(Thermo Fisher Scientific) reagent according to the 
manufacturer’s protocol. After 48 h cells were collected. 
Cells were lysed in M- PER® (Mammalian Protein 
Extraction Reagent, Thermo Fisher Scientific) containing 
complete protease inhibitors cocktail (Sigma- Aldrich, 
Saint Louis, Missouri, USA) and analyzed by western 
blotting. The intensity of the western blotting bands 
was measured by Image Lab Software (Bio- Rad) and 
expressed as arbitrary unit (AU). The highest value 
obtained was assigned as 1.
Bioinformatics and statistical analyses
All the variants found in the sequencing experiment were 
functionally annotated using the hTERT RefSeq reference 
transcript NM_001193376. We defined rare coding muta-
tions as variations not present in dbSNP (release 147) and 
1000 Genomes Project (Phase 3) or described with a minor 
allele frequency (MAF) <0.001 according to ExAC NFE 
and ESP EA populations. The rare variants identified were 
submitted to the ClinVar database (www.ncbi.nlm.nih.gov/
clinvar/; submission ID: SUB2041085 [MDI- 7607]).
For descriptive statistics, continuous variables are shown 
as mean and standard deviation, while categorical variables 
are presented as number and proportion. Telomere lengths 
comparisons have been conducted by generalized linear 
model corrected for sex and age.
Burden test was performed using the collapsing method 
CAST (Cohort Allelic Sum Test) available in the R pack-
age AssotesteR (http://CRAN.R-project.org/package= 
AssotesteR). Briefly, the genotype of the rare coding muta-
tions for the individual of each group of patients and 
controls was summarized and collapsed into a single genetic 
score, taking into account both the number of mutated 
alleles in each group and the mutation frequency in con-
trols. The association of this score with the trait was 
tested using Fisher’s test. The association was considered 
statistically significant with P values lower than 0.05.
The impact of rare coding mutations on protein activity 
was predicted in silico by different bioinformatics algo-
rithms including Polyphen- 2 (http://genetics.bwh.harvard.
edu/pph2/), SIFT (http://sift.jcvi.org) and PROVEAN 
(http://provean.jcvi.org).
Statistical analyses were carried out using the JMP 12.0 
statistical analysis software (SAS Institute, Cary, NC) and 
R statistical analysis software version 3.3.2 (http://www.R-
project.org/). Ps < 0.05 were considered statistically sig-
nificant. The study methods and results have been reported 
according to the STROBE/STREGA guidelines for genetic 
association studies.
Results
Telomere length is reduced in peripheral 
blood leukocytes of NAFLD- HCC patients
Telomere length in peripheral blood leukocytes decreased 
with liver disease progression from healthy controls to 
NAFLD- cirrhosis to NAFLD- HCC (P = 0.005). The trend 
for shortening was maintained after adjusting the analysis 
for sex and age (P = 0.0002; Fig. 1A). In particular, telomere 
length was shorter in patients with HCC than in those 
with cirrhosis (median: 0.93 IQR: 0.66–1.24 vs. 1.12 IQR: 
0.82–1.69; P = 0.014), and in healthy subjects (median: 
1934 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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1.38 IQR: 0.99–1.75; P = 0.0001). In an independent vali-
dation cohort of 50 Italian NAFLD- HCC patients, we also 
detected a significant shortening of telomere length as com-
pared to controls (NAFLD- HCC validation cohort median: 
1.12 IQR: 0.80- 1.60; P for trend=0.048; Fig. 1B). When we 
considered the overall cohort of NAFLD- HCC samples evalu-
ated (n = 89), the trend for shortening was again highly 
significant (P = 0.003), with NAFLD- HCC patients having 
shorter telomeres as compared even to those with uncom-
plicated cirrhosis and to healthy individuals (NAFLD- HCC 
overall cohort median: 0.98 IQR: 0.77–1.52; P = 0.048 and 
P = 0.0006, respectively; Fig. 1C).
Rare hTERT coding mutations are enriched in 
NAFLD- HCC patients
The main study aim was to evaluate the prevalence of 
rare hTERT coding variants in NAFLD- HCC patients. In 
the discovery cohort made up of Italian NAFLD- HCC 
patients, we found four (three novel and one previously 
described) mutations. In particular, one HCC patient car-
ried a frameshift mutation, Glu113Arg_fs*79, in the second 
exon of the sequence (Fig. 2 and Figure S2). Three NAFLD- 
HCC patients carried missense mutations: Ala67Val, 
Pro193Leu, and Glu668Asp. The Ala67Val and Pro193Leu 
are both located in the N- terminal (template- binding 
domain). The Glu668Asp mutation is located in the cata-
lytic domain (Fig. 2). All but the Ala67Val mutations 
were detected in heterozygosity. There was a significant 
enrichment in hTERT rare coding variants in NAFLD- 
HCC patients as compared to local controls consistent 
of patients with NAFLD- cirrhosis or healthy individuals, 
where no mutations were identified (mutated alleles preva-
lence 10%; P = 0.022 vs. cirrhosis, P = 0.008 vs. healthy 
subjects; P = 0.001 vs. controls overall). Burden test analysis 
confirmed the enrichment of rare hTERT coding 
Figure 1. Telomere length is reduced in peripheral blood leukocytes of NAFLD- HCC patients. Relative telomere length of patients included in the 
discovery cohort (A), in the validation cohort (B), and in the overall cohort (C) was reported in the figure. Overall cohort includes all the Italian NAFLD- 
HCC patients (see Table 1). For the different comparison P values were calculated by linear generalized model corrected for sex and age considering 
log- transformed data (Table S2). For all the specimens, telomere length was evaluated by qPCR as ratio of the relative quantity of the telomere PCR 
product and the reference gene (36B4).
Figure 2. Rare coding mutations found in hTERT gene. Schematic representation of hTERT sequence showing the distribution of the rare coding 
mutations identified in the different domains.
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mutations in NAFLD- HCC (P = 0.020 vs. healthy controls; 
P = 0.045 vs. cirrhosis; Table 2). When we extended the 
control group to the 503 healthy European subjects from 
the 1000 Genomes Project database (http://www.interna-
tionalgenome.org/faq/can-i-get-phenotype-gender-and-
family-relationship-information-samples), in which only 
one individual of Italian origin was a heterozygous carrier 
of a rare coding mutation in hTERT, we confirmed a 
strong enrichment of hTERT mutations in NAFLD- HCC 
(P = 0.0001; Table 2).
Interestingly, considering the distribution of known rare 
coding mutations in hTERT (see Telomere Database—
http://telomerase.asu.edu), we observed an enrichment of 
variations in the N- terminal of the gene (P = 0.037), as 
compared to catalytic and C- terminal domains.
Besides rare variants, common missense mutations in 
hTERT were found in HCC and cirrhotic patients and 
healthy controls, at the expected frequencies (Ala279Thr, 
His412Tyr, and Ala1062Thr; Table S3).
hTERT mutations in a European cohort of 
NAFLD- PLC patients
We further sequenced hTERT in an independent cohort 
comprising 78 patients affected by PLC in NAFLD, 64% 
of Italian origin, 97% with HCC (Table 1). Here, we found 
one heterozygous carrier of a rare missense mutation 
(His296Pro; Fig. 2 and Figure S2) affected by intrahepatic 
cholangiocarcinoma. There was no significant enrichment 
in hTERT mutations between the validation cohort and 
controls (P=NS). However, when we considered the overall 
cohort of cancer patients (n = 118), as compared to all 
available controls (from discovery cohort and the 1000 
Genomes database, n = 612), we confirmed a significant 
enrichment of rare germline hTERT variants in subjects 
affected by tumor developed in NAFLD (P = 0.0005; 
Table 2), which remained significant after the exclusion 
of the only two PLC patients without HCC (P = 0.003).
Clinical features of patients carrying rare 
hTERT mutations
The clinical features of patients positive and negative for 
the presence of the rare hTERT mutations are shown in 
Table 3. We found that the prevalence of female sex was 
higher in carriers of hTERT mutations (P = 0.03). We 
did not observe any significant difference in the distribu-
tion of age, BMI, diabetes, and the presence of cirrhosis 
between the two groups (P = NS). The genetic risk factor 
PNPLA3 I148M was equally distributed between the two 
groups (P = 0.88). No significant difference was detected 
in peripheral blood telomere length between patients posi-
tive and those negative for hTERT mutations (not shown). Ta
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Family study
To investigate the pathogenicity of the mutations identi-
fied, we examined whether these cosegregated with liver 
disease or other pathological phenotypes. We were able 
to genotype and phenotype some relatives of the probands 
carrying the Glu668Asp (Family A, Figure S3) and 
Glu113Argfs (Family B, Figure S3) mutations. In Family 
A, one son of the proband carried the mutation in het-
erozygosity and already showed traits of liver damage 
(NAFLD and increased liver enzymes) despite a relatively 
young age. Moreover, the mother and the sister of the 
proband were affected by a phenotype very likely related 
to telomere disease (cryptogenic cirrhosis and idiopathic 
pulmonary fibrosis, respectively), but they were already 
deceased at the time of the referral and could not be 
evaluated. In Family B, the proband’s brother, who also 
carries the Glu113Argfs mutation, has altered liver func-
tion tests. One of the younger daughters and a nephew 
of the proband are also heterozygous carriers of the muta-
tion but with no phenotypic signs, possibly due to the 
young age.
Functional evaluation of hTERT mutations
In order to investigate whether the mutations found could 
affect the catalytic activity of hTERT, their effect was 
modeled in silico using predictive bioinformatics algo-
rithms. In addition to the Glu113Argfs frameshift muta-
tion, which causes a premature termination of protein 
synthesis and is frankly damaging, the Glu668Asp variant 
was also predicted to be deleterious by two out of three 
prediction tools (Table S4). Conversely, the amino acid 
substitutions Ala67Val, Pro193Leu, and His296Pro were 
not predicted to disrupt the activity of the protein (Table 
S4), which does not rule out that they may impact on 
the DNA binding of TERT.
To gain further insight into the consequences of hTERT 
mutations, we transiently overexpressed the wild- type and 
the missense mutants in human HEK- 293 cells. We 
observed a substantial reduction in the recombinant intra-
cellular protein synthesis of the Ala67Val and Glu668Asp 
mutations as compared to the wild- type protein (Fig. 3). 
There was virtually no change in the protein synthesis 
of the Pro193Leu and His296Pro mutants as compared 
to the wild- type protein (Figure 3).
Discussion
NAFLD- HCC is an increasingly common cause of liver- 
related mortality in Western countries, due to rising inci-
dence and lack of adequate biomarkers allowing early 
Table 3. Clinical features of 118 patients who developed primary liver 
cancer (PLC) in NAFLD stratified by carriage of rare hTERT mutations.
hTERT mutation
PLC cohort overall
PYes (n = 5) No (n = 113)
Age, years 70.4 ± 10.8 67.0 ± 8.8 0.52
Sex, F 3 (60) 21 (19) 0.03
BMI, kg/m2 28.8 ± 5.0 29.9 ± 5.3 0.65
T2DM, y 3 (60) 66 (58) 0.94
Fibrosis, F3- 4 4 (80) 89 (79) 0.93
PNPLA3, I148M 0.90
I/I 1 (20) 30 (27)
I/M 2 (40) 48 (42)
M/M 2 (40) 35 (31)
HCC/CC 4/1 (75/25) 112/1 (99/1) 0.001
PLC, primary liver cancer; (), % values; y, yes; T2DM, type 2 diabetes mel-
litus; P, P value calculated as patients carriers of hTERT mutations versus 
not carriers; HCC, hepatocellular carcinoma; CC, cholangiocarcinoma.
Figure 3. The hTERT Ala67Val and Glu668Asp variants result in a reduction of the intracellular protein levels. Effect of missense mutations on hTERT 
protein levels in HEK- 293 cells (A). Human TERT was transiently overexpressed in HEK- 293 cells. HEK- 293 cells were transfected with hTERT wild- type 
and mutant forms cloned in pcDNA 3.1 vector for 48 h; recombinant hTERT protein levels were examined on cell lysate by western blotting analysis 
by using a V5 antibody. Empty vector was used as negative and calnexin was used as loading control. Quantification of western blotting bands (B). 
The graph bar represents intracellular protein levels expressed as mean and standard deviation (whisker) of three independent experiments. Protein 
levels were quantified by Image Lab Software (Bio- Rad).
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diagnosis [1]. NAFLD and HCC have a heritable com-
ponent, but the genetic determinants influencing onset 
and progression of HCC remain mostly unknown, with 
rare genetic mutations possibly playing a role in triggering 
disease development [8, 9, 13]. In this study, we examined 
whether mutations in hTERT, a key player in hepatic 
fibrosis progression and carcinogenesis [14, 17, 21, 32], 
are associated with NAFLD- HCC development.
Consistently with literature data obtained in other liver 
diseases [25], we observed a progressive shortening of 
peripheral telomere length, from healthy controls to patients 
with NAFLD- cirrhosis and finally to those who developed 
HCC. This trend for shortening was confirmed in two 
independent groups of NAFLD- HCC patients as compared 
to a local cohort of patients with cirrhosis and healthy 
individuals, but the lack of an independent cohort of 
patients with NAFLD- cirrhosis at high risk of HCC rep-
resents a limitation of this study. In keeping with these 
observations, previous studies demonstrated that telomere 
attrition is involved in the progression of liver disease, 
as well as in other chronic degenerative conditions [21, 
22, 33, 34]. Indeed, shorter telomeres most likely lead to 
exhaustion of tissue staminal compartments, senescence, 
and fibrosis, which may involve the lung, liver, and blood, 
and predispose to a wide spectrum of cancers by favoring 
genomic instability [35]. Not only genetic alterations in 
telomerase complex genes, but also environmental risk 
factors for degenerative diseases, such as smoke and pol-
lution, have been associated with peripheral blood telomere 
shortening, reflecting whole body exposure [34, 36]. It is 
therefore possible that shorter telomeres may reflect both 
genetic predisposition and environmental factors exposure 
in NAFLD- HCC patients (Fig. S4). However, it should 
be specified that our data indicate that despite it is asso-
ciated with NAFLD- HCC, shorter telomere length of 
peripheral blood leukocytes lacks sufficient diagnostic 
accuracy to be considered a novel biomarker to stratify 
HCC risk.
The main study hypothesis was that hTERT germline 
mutations favor the development of HCC in NAFLD. We 
focused on rare germline mutations determining an altera-
tion of protein sequence because these are more likely 
to alter protein function [37, 38]. Consistently, in the 
NAFLD- HCC discovery cohort, we observed a strong 
enrichment in rare and novel hTERT mutations, more 
than 76- fold as compared to the frequency of analogous 
mutations in local controls and healthy individuals of 
matched ethnicity in public databases. In further analysis, 
we considered as population controls only apparently 
healthy Europeans individuals included in the 1000 
Genomes database. These data are consistent with the 
hypothesis that rare hTERT mutations predispose to 
NAFLD- HCC.
The frequency of hTERT mutations was lower in a 
larger European validation cohort, but among NAFLD- 
PLC patients (most of them affected by HCC) overall 
there still was a significant 31- fold enrichment in hTERT 
mutations. The higher prevalence of mutations in the 
discovery cohort may possibly be ascribed to a higher 
proportion of individuals without strong cofactors for 
progressive NAFLD such as obesity and male sex, so that 
genetic factors may have played a larger role. Interestingly, 
despite HCC more frequently developing in males, we 
observed a higher prevalence of hTERT mutations in female 
patients with NAFLD- PLC, so that the lower proportion 
of females in the validation cohort may have reduced the 
probability of finding mutations carriers. As one mutation 
carrier was actually diagnosed with intrahepatic cholan-
giocarcinoma, we cannot exclude the possibility that hTERT 
genetic variations represent a pathogenic risk factor also 
for cholangiocarcinoma, but conclusions could not be 
drawn based on a single case. Despite we have studied 
the largest cohort of NAFLD- HCC patients with genetic 
characterization so far reported, collaborative prospective 
studies are needed in order to confirm this association 
in a larger cohort, as well as in non- European 
individuals.
On the other hand, common missense variants in hTERT, 
including Ala279Thr, His412Tyr, and Ala1062Thr, previ-
ously reported to confer increased risk of telomere disease 
[39–41], were not differently represented between HCC 
cases and healthy controls. Even if these genetic variants 
may possibly confer subtle alterations in hTERT activity, 
we can reasonably exclude that they have a strong impact 
on telomere dysfunction; otherwise they would have under-
gone a strong negative selection (purification) during 
evolution. Our study was not sufficiently powered to detect 
a moderate effect on the risk of progressive NAFLD.
Besides the fact that are rare or novel mutations, other 
clues suggest a role for the identified genetic variants in 
the pathogenesis of NAFLD- HCC. The first one is that 
mutations tended to cosegregate within the N- terminal 
domain of hTERT, which is involved in telomere binding. 
Indeed, it is know that mutations in specific hTERT 
domains tend to determine specific pathological phenotypes 
[35]. Second, in two families mutations cosegregated with 
liver disease and other phenotypes shared by telomere 
diseases in older individuals. As telomeropathies are age- 
dependent degenerative conditions, a longer follow- up will 
be necessary to better characterize the penetrance of these 
genetic variants in younger carriers. Furthermore, in silico 
analysis predicted functional consequences for Glu113Arg_
fs, determining an early termination of protein and the 
Glu668Asp mutation in the catalytic domain. However, 
the ability of bioinformatics tools to predict the interac-
tion of the other N- terminal domain mutations with 
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telomeres and interacting proteins is quite limited, as they 
are built to predict how an amino acid substitution influ-
ence protein activity.
To gain further insight into the functional consequences 
of hTERT mutations, we transiently overexpressed the 
wild- type and the missense variants. We did not test in 
vitro the Glu113Argfs*79 mutation because of the high 
likelihood to undergo mRNA decay due to the severe 
damage caused by the frameshift [42]. We observed that 
the Ala67Val and the Glu668Asp mutations resulted in 
a severe reduction in the intracellular protein levels as 
compared to the wild type, suggesting that the Ala67Val, 
carried in homozygosity by one NAFLD- HCC patient, 
may induce a reduction in telomerase expression due to 
altered protein translation or stability. On the other hand, 
the remaining two mutations detected in NAFLD- HCC 
patients without a clear pathogenic effect: the Pro193Leu 
and His296Pro mutations in the N- terminal template- 
binding domain, that do not likely influence the catalytic 
activity of hTERT, but may result in a reduction of the 
binding ability of hTERT, inducing novel telomerase func-
tions in tumorigenesis independently of hTERC [43]. For 
example, hTERT can act as a transcription factor in the 
Wnt- β- catenin signaling pathway, regulating the expression 
of procarcinogenic Wnt target genes [44]. As the bioin-
formatics and in vitro approaches were not suitable to 
test these hypotheses and to evaluate the effective impact 
of these mutations on the different functions of telomerase, 
further studies are required to better investigate their pos-
sible causal role and mechanism in determining HCC 
predisposition.
As many other proteins are included in telomerase 
complex and participate to telomere elongation, we cannot 
exclude that mutations in other genes involved in telomere 
regulation play a role in telomere attrition in NAFLD- 
HCC. Indeed, telomere length in peripheral blood was 
shortened irrespective of the presence of hTERT mutations 
in NAFLD- HCC patients. Additional genetic factors should 
be investigated by next- generation sequencing in order 
to examine whether carriage of rare genetic risk variants 
may account for apparently sporadic cases of NAFLD- 
HCC. In fact, our approach suggests that rare germline 
mutations altering the sequence of protein known to be 
involved in the pathogenesis of NAFLD and chronic liver 
disease may play an important role in NAFLD- HCC pre-
disposition, representing useful biomarkers for risk strati-
fication, particularly in family members of affected 
individuals.
In conclusion, we detected an association between shorter 
peripheral blood telomeres and NAFLD- HCC development, 
and found that rare germline mutations in hTERT seems 
predispose to NAFLD progression to HCC, potentially 
assisting the identification of high- risk individuals that 
may warrant closer surveillance and may be included in 
chemopreventive trials.
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